These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29567312)

  • 1. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
    Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
    Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
    Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
    Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
    Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.
    Heemskerk MH; Hoogeboom M; de Paus RA; Kester MG; van der Hoorn MA; Goulmy E; Willemze R; Falkenburg JH
    Blood; 2003 Nov; 102(10):3530-40. PubMed ID: 12869497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell Receptors for Clinical Therapy:
    Kunert A; Obenaus M; Lamers CHJ; Blankenstein T; Debets R
    Clin Cancer Res; 2017 Oct; 23(20):6012-6020. PubMed ID: 28645940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
    Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM
    Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR Fingerprinting and Off-Target Peptide Identification.
    Karapetyan AR; Chaipan C; Winkelbach K; Wimberger S; Jeong JS; Joshi B; Stein RB; Underwood D; Castle JC; van Dijk M; Seibert V
    Front Immunol; 2019; 10():2501. PubMed ID: 31695703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
    Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
    Front Immunol; 2019; 10():2076. PubMed ID: 31552033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
    Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
    Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD; Harris DT; Kranz DM
    Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
    Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
    Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Studies of the Off-Target Reactivity of AFP
    Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
    Front Immunol; 2020; 11():607. PubMed ID: 32395117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
    Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
    Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.